Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Accumulated Expenses (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Accumulated Expenses for 10 consecutive years, with $940000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 80.57% to $940000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $940000.0 through Dec 2025, down 80.57% year-over-year, with the annual reading at $940000.0 for FY2025, 80.57% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $940000.0 at Rein Therapeutics, up from $710000.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $4.8 million in Q4 2024, with the low at $103000.0 in Q3 2023.
  • Average Accumulated Expenses over 5 years is $2.0 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses crashed 97.08% in 2023, then skyrocketed 1538.62% in 2024.
  • Over 5 years, Accumulated Expenses stood at $1.2 million in 2021, then skyrocketed by 37.99% to $1.6 million in 2022, then soared by 92.95% to $3.1 million in 2023, then surged by 53.73% to $4.8 million in 2024, then plummeted by 80.57% to $940000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $940000.0, $710000.0, and $640000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.